Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2026 Earnings Call Transcript April 30, 2026Phathom Pharmaceuticals, Inc. misses on earnings expectations.
Phathom Pharmaceuticals Inc. (PHAT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Persistent Asset Partners Xin Huang | 47,663 | $517,143 | +79% | 0.15% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.86 | 3,780 | $14,609.32 | 59,403 | 2025-05-21 | Filing | |
| $3.32 | 6,300 | $20,919.15 | 55,623 | 2025-05-14 | Filing | |
| $3.16 | 1,120 | $3,543.34 | 49,323 | 2025-05-13 | Filing | |
| $3.04 | 12,601 | $38,300.74 | 48,203 | 2025-05-12 | Filing | |
| $3.62 | 2,226 | $8,053.00 | 35,602 | 2025-05-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.51 | 524 | $7,079.24 | 47,407 | 2025-11-03 | Filing | |
| $12.09 | 461 | $5,573.49 | 47,931 | 2025-09-05 | Filing | |
| $8.36 | 1,692 | $14,151.72 | 48,392 | 2025-07-16 | Filing | |
| $4.55 | 3,678 | $16,739.68 | 89,868 | 2025-04-07 | Filing | |
| $6.59 | 6,583 | $43,370.78 | 93,546 | 2025-01-21 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,464,572 | $80,990,606 | 45.65% | |
| 2. | 4,525,129 | $49,097,648 | 0% | |
| 3. | 3,496,808 | $37,940,367 | 0.38% | |
| 4. | 1,586,323 | $17,211,605 | 0% | |
| 5. | 1,493,854 | $16,208,316 | 7.06% |
News See All
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is one of the best cheap biotech stocks to buy now. Guggenheim lifted the price target on Phathom Pharmaceuticals, Inc.
12 Cheap Biotech Stocks to Buy Now
On February 27, Eli Casdin, Casdin Capital CEO, appeared on CNBC’s ‘Closing Bell’ to talk about the biotech sector.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2025 Earnings Call Transcript February 26, 2026Phathom Pharmaceuticals, Inc. beats earnings expectations.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Phathom Pharmaceuticals' Third Quarter 2025 Earnings Results Call. [Operator Instructions] Please be advised that today's call is being recorded.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call Transcript August 7, 2025Phathom Pharmaceuticals, Inc. misses on earnings expectations.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript May 1, 2025Phathom Pharmaceuticals, Inc. misses on earnings expectations.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call. At this time, all participants are in a listen-only mode.
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?
PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2024 Earnings Results Call. At this time, all participants are in a listen-only mode.
Hedge Fund Resource Center